Pfizer Price to Book Ratio 2010-2024 | PFE

Historical price to book ratio values for Pfizer (PFE) over the last 10 years. The current price to book ratio for Pfizer as of June 19, 2024 is 1.68.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Pfizer Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2024-06-18 27.41 1.68
2024-03-31 27.34 $16.33 1.67
2023-12-31 27.94 $15.81 1.77
2023-09-30 31.75 $17.22 1.84
2023-06-30 34.72 $17.59 1.97
2023-03-31 38.20 $17.93 2.13
2022-12-31 47.54 $17.08 2.78
2022-09-30 40.25 $16.55 2.43
2022-06-30 47.85 $15.64 3.06
2022-03-31 46.87 $14.79 3.17
2021-12-31 53.07 $13.78 3.85
2021-09-30 38.31 $13.54 2.83
2021-06-30 34.57 $12.56 2.75
2021-03-31 31.67 $12.31 2.57
2020-12-31 31.83 $11.40 2.79
2020-09-30 29.78 $11.79 2.53
2020-06-30 26.28 $11.62 2.26
2020-03-31 25.96 $11.77 2.21
2019-12-31 30.85 $11.46 2.69
2019-09-30 28.01 $11.82 2.37
2019-06-30 33.46 $10.77 3.11
2019-03-31 32.52 $10.65 3.05
2018-12-31 33.14 $11.15 2.97
2018-09-30 33.20 $12.40 2.68
2018-06-30 27.10 $11.96 2.27
2018-03-31 26.25 $12.06 2.18
2017-12-31 26.55 $11.98 2.22
2017-09-30 25.93 $10.25 2.53
2017-06-30 24.16 $9.87 2.45
2017-03-31 24.37 $9.84 2.48
2016-12-31 22.91 $9.86 2.32
2016-06-30 24.38 $10.40 2.35
2016-03-31 20.34 $10.44 1.95
2015-12-31 21.93 $10.53 2.08
2015-09-30 21.17 $10.87 1.95
2015-06-30 22.42 $10.89 2.06
2015-03-31 23.07 $10.98 2.10
2014-12-31 20.48 $11.38 1.80
2014-09-30 19.27 $12.43 1.55
2014-06-30 19.17 $12.14 1.58
2014-03-31 20.57 $12.24 1.68
2013-12-31 19.45 $11.97 1.62
2013-09-30 18.10 $12.09 1.50
2013-06-30 17.50 $11.93 1.47
2013-03-31 17.88 $11.68 1.53
2012-12-31 15.41 $11.23 1.37
2012-09-30 15.13 $11.15 1.36
2012-06-30 13.87 $10.71 1.30
2012-03-31 13.53 $11.17 1.21
2011-12-31 12.80 $10.91 1.17
2011-09-30 10.35 $11.78 0.88
2011-06-30 11.93 $11.40 1.05
2011-03-31 11.65 $11.46 1.02
2010-12-31 9.94 $11.02 0.90
2010-09-30 9.64 $10.99 0.88
2010-06-30 7.92 $10.81 0.73
2016-09-30 23.65 $10.48 2.26
2010-03-31 9.43 $11.17 0.84
2009-12-31 9.91 $11.21 0.88
2009-09-30 8.93 $8.21 1.09
2009-06-30 8.01 $9.37 0.86
2009-03-31 7.19 $8.96 0.80
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $155.321B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Novo Nordisk (NVO) Denmark $631.845B 48.55
Johnson & Johnson (JNJ) United States $350.533B 13.92
Merck (MRK) United States $324.174B 58.98
AbbVie (ABBV) United States $302.599B 15.64
AstraZeneca (AZN) United Kingdom $243.139B 21.14
Novartis AG (NVS) Switzerland $214.497B 15.21
Sanofi (SNY) $119.456B 11.27
Innoviva (INVA) United States $1.013B 7.11